The retinoic acid receptor a (RARa) and the my1 gene are involved in the translocation breakpoint t(15;17)(q22;q21) in acute promyelocytic leukemia (APL). The majority of the breakpoint sites have been mapped within the second intron of the RARa gene; however, the breakpoint sites on the my1 gene are variable. Using primer sets derived from exon 2 or exon 3 of the RARa gene and a primer derived from the my1 cDNA, we were able to amplify the breakpoint sites of the fusion transcripts of all six APL RNA samples by the reverse transcriptase-polymerase chain reaction (RT-PCR). A DNA fragment of 290 bp (breakpoint A) was amplified using RNA samples from three patients, whereas two DNA fragments of 630 and 774 bp (breakpoint B) were amplified using RNA HE NONRANDOM translocation breakpoint t(l5; T 17)(q22;q21) is present in patients with acute promyelocytic leukemia (APL). Interestingly, APL can be treated with all-trans retinoic acid (ATRA) to achieve complete Recently, several laboratories have shown that the breakpoint site occurs within the structural gene of the retinoic acid receptor a (RARa) on chromosome 17 and the my1 gene on chromosome 15.5-8 RARa is a transcription regulator that has been shown to regulate expression of many genes."" Hybrid mRNAs of myllRARa and RARa/ my1 transcribed from the breakpoint sites have been cloned and characterized."," The fusion transcript myllRARa consists of the DNA and ligand-binding domains of RARa, whereas the N-terminal region of RARa is thought to be involved in transactivation and is translocated to the upstream region of the my1 gene. Transcription of this fusion gene results in the hybrid mRNA RARalmyl."
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HE NONRANDOM translocation breakpoint t(l5;
T 17)(q22;q21) is present in patients with acute promyelocytic leukemia (APL). Interestingly, APL can be treated with all-trans retinoic acid (ATRA) to achieve complete Recently, several laboratories have shown that the breakpoint site occurs within the structural gene of the retinoic acid receptor a (RARa) on chromosome 17 and the my1 gene on chromosome 15.5-8 RARa is a transcription regulator that has been shown to regulate expression of many genes."" Hybrid mRNAs of myllRARa and RARa/ my1 transcribed from the breakpoint sites have been cloned and characterized."," The fusion transcript myllRARa consists of the DNA and ligand-binding domains of RARa, whereas the N-terminal region of RARa is thought to be involved in transactivation and is translocated to the upstream region of the my1 gene. Transcription of this fusion gene results in the hybrid mRNA RARalmyl."
We have cloned and characterized the cDNA of RARa/ my1 and the my1 gene," and now, using these two cDNA sequences, we have designed a strategy to amplify the t (15;17) polymerase chain reaction (PCR). We found that the breakpoint sites clustered within two regions of the my1 gene and we were able to detect minimal residual cells containing the t(15;17) transcript in five APL patients in complete remission.
MATERIALS AND METHODS
Oligonucleotide primers. Oligonucleotide primers 5 'TGGTCT-GAAGCCCACCAGAC3' (R5) and 5'CTGACCACTCTCCAG-CACCA3' (Rl) were derived from the cDNA sequence as reported by Giguere et al." The oligonucleotide primers 5'TTCGGCATCTGAGTCTTC3' (D4) and S'ACCTCCAAG-GCAGTCTCACCAC3' (U6) were synthesized according to the my1 cDNA.'* Taq DNA polymerase was obtained from PerkinElmer Cetus (Norwalk, CT).
The breakpoint sites of the fusion transcripts were amplified according to the method previously described,14." with some modifications. The reaction contained 1 mol/L each of dNTP, 20 U of RNasin (Promega Corp, Madison, WI), 5 p,g of total RNA, 10 ng downstream primer (D4), and 200 U Maloney Murine Leukemia Virus reverse transcriptase. This mixture was incubated at room temperature for 10 minutes, followed by incubation at 42°C for 45 minutes. At the end of incubation, the reaction mixture was heated to 95°C for 10 minutes and quick chilled on ice. Five microliters of the reaction mixture was removed and used in a PCR reaction as described." Each cycle was performed for 1 minute at 94"C, 1 minute at 62T, and 2 minutes at 72°C. A total of 35 cycles was usually sufficient to amplify the target sequences.
Amplification of genomic DNA sequence was performed by using 1 p,g of genomic DNA. After heat denaturation at lOO"C, 3 minutes, 0.2 p,g each of D4 and U6,200 kmol/L dNTP, and 2.5 U of Taq-polymerase were added. PCR was performed for 35 cycles and each cycle was performed for 1 minute at 9 4 T , 1 minute at 55"C, and 2 minutes at 72°C. The DNA fragments were first purified of primers by passing them through a Centricon-100 (Amicon, Beverly, MA). Approximately 0.1 p,g of the purified DNA was then used in an asymmetric PCR using the downstream primer (D4). After PCR, single-stranded DNA was purified in the Centricon-100 and used directly in the DNA sequencing reaction. DNA sequencing was performed in the Northem blot anatysk. Total RNA was isolated from the leukemic cells and Northem blotting was performed as previously described.16
RESULTS
A strategy for PCR amplijication of the APL t(15;17) breaeint site. The translocation breakpoint of APL occurs within the second intron of the RARa gene. Therefore, specific breakpoint sites can be PCR amplified using oligonucleotide primers synthesized from the 3' end of exon 2 or the 5' end of exon 3 of the RARa gene and a primer derived from the nucleotide sequence of the my1 cDNA. Using a combination of different primer sets, one should be able to amplify the breakpoint sites in all t( 15;17)-positive APL samples. Using this approach, we selected six APL patients with t(15;17) in which to study the breakpoint sites on the my1 gene. After several attempts, we found that the primer set R5/D4, which specifically amplified the fusion transcript RARalmyl, was able to amplify a fragment of 290 bp using RNA extracted from three APL bone marrow samples (lanes 1 through 3, Fig 1) . Because all three amplified fragments appeared to be identical in size, the breakpoint sites of these patients may be similar or occur within the same intron of the my1 gene. Using the same primer set, fragments of 630 and 774 bp were amplified using RNA extracted from bone marrow samples of patients 4, 5, and 6 (Fig l) . The amplified fragments in all these samples also appeared to be similar in size. These results suggest that the t( 15;17) breakpoint in APL occurs at two different sites on the my1 gene.
DNA sequence anabsis of the PCR-amplijied DNA Pagments. A small quantity of the PCR-amplified DNA fragments was used to generate single-stranded DNA by asymmetric PCR as described in Materials and Methods. DNA sequencing was performed using an internal primer (Rl). These results demonstrated that the DNA sequences of the RARalmyl fusion transcripts of patients 1, 2, and 3 (Fig 2A) are identical. Similarly, DNA sequences of the fusion transcripts of patients 4,5, and 6 (Fig 2B) were also found to be identical. Therefore, the breakpoint sites of the six APL patients clustered within two different sites. The amplification of two DNA fragments of 630 and 774 bp for breakpoint site A is the result of alternative splicing of the 144-bp fragment located 70 bases downstream of breakpoint site A." The two breakpoint sites on the my1 gene appear to occur within the intron region of the gene. Using the genomic DNA of non-APL samples and a primer set derived from both sides of breakpoint site B, we were able to amplify a 1.3-kb DNA fragment. DNA sequence analysis of both ends of this DNA fragment confirmed that this breakpoint site occurs within an approximately 1.25-kb intron of the my1 gene (Fig 3) . A similar approach was used to amplify the intron of breakpoint site A, but was unsuccessful. This would suggest that an intron exists within this region, but is too large to be amplified by PCR. In the absence of an intron, a DNA fragment of about 150 bp would have been amplified. We are currently characterizing the my1 genomic DNA, to clarify this issue.
Based on the previous reports by different groups, it appears that two different patterns of fusion transcripts were found in APL patients using the RARa cDNA as a hybridization
Northem blot analysis of the fusion transcripts.
For prObe.12.17.18 Because most of the breakpoint sites of APL occur within the second intron of the RARa gene, different sizes of fusion transcripts seen in different APL patients must have resulted from different breakpoint sites on the my1 gene. To confirm this, a Northern blot analysis was performed using the RNA samples obtained from the six APL patients as described above. As shown in Fig. 4A using an exon 3-9 RARa cDNA as a hybridization probe, all patients expressed the two normal RARa mRNA of 2.7 and 3.7 kb. However, patients 1, 2, and 3 with breakpoints occurring on site A (Fig 3) expressed two fusion transcripts of 4.2 and 3.2 kb, whereas patients 4. 5, and 6 with breakpoints occurring on site B expressed fusion transcripts of 4.6 and 3.6 kb. Because the RARa cDNA used in this experiment lacks exon 1 and exon 2, these fusion transcripts should represent the myllRARa. The same Northern blot was hybridized to a 0.9-kb my1 cDNA (nucelotides 1440 to 0 1 2 3 4 5 6 Fig. 4B , an abnormal mRNA of 2.6 kb in addition to the 3.2-kb normal my1 mRNA was found in patients 1, 2, and 3. An abnormal mRNA of 2.1 kb was found in patients 4, 5, and 6, in addition to the 3.2-kb normal my1 mRNA. Because this my1 cDNA probe lacks the DNA sequence of the myllRARa, the 2.1-and 2.6-kb abnormal mRNA should represent the RARAalmyl. These results suggest that size heterogeneity in the fusion transcripts in APL patients results from the variation in different breakpoint sites on the my1 gene. We have previously shown that the two RARa mRNA species (2.7 and 3.7 kb) are the result of different polyadenylation sites.'* In APL, the transcription of myllRARa should not affect the use of the two different polyadenylation sites, thus generating two fusion transcripts of either 3.2 and 4.2 kb or 3.6 and 4.6 kb in APL patients.
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We have analyzed bone marrow samples from five APL patients who were in complete remission based on clinical status, bone marrow morphology, normal cytogenetics, and Southern blot analysis. Samples from these five patients were the first remission bone marrow samples taken after induction therapy. Breakpoints in two of these patients were found to be at site B during the acute phase. Using similar conditions as described in Materials and Methods (except that a 45-cycle PCR was used), a DNA fragment of 290 bp was amplified for both samples (Fig 5A) . DNA sequence analysis confirmed that these DNA fragments were indeed derived from the fusion transcript RARalmyl (data not shown). Interestingly, one of the two patients relapsed 16 months after the first and only PCR sample was tested. The second patient remains in remission after 6 months of follow-up. Three other APL samples in remission were analysed by reverse transcriptase (RT)-PCR and all were positive (Fig 5B) . One patient remains in remission for 6 months and two patients are in remission after 7 months of follow-up. Two patients demonstrated the breakpoint at site A and one had the breakpoint at site B.
Sensitivity of the RT-PCR in the detection of t(15;17) breakpoint in APL. To determine the sensitivity of the RT-PCR in our study, two APL patient samples (one with breakpoint at site A and the other at site B) were selected, serially diluted, and a 35-cycle PCR was performed as described in Materials and Methods. As shown in Fig 6, the RT-PCR can detect the breakpoint in the presence of 0.1 ng total RNA, which represents a 104-fold dilution.
Detection of minimal residual disease in APL.
DISCUSSION
We and others have demonstrated that the chromosomal abnormality t (15;17) in APL occurs within the 17-kb intron 2 of the RARa gene."' Furthermore, results of Southern blot analysis indicate that the breakpoint sites within intron 2 of the RARa gene in APL can be variable. Therefore, it is not feasible to PCR amplify the breakpoint in APL using genomic DNA. However, our findings indicate that the t( 15;17) breakpoint clusters at two different sites on the my1 mRNA that are separated by about 400 bp. Using a single analyzed; the PCR-amplified DNA fragments were restriction digested with I@nl and electrophoresed in a 1.2% agarose gel. Lanes 1, 3, and 5 are undigested PCR amplified DNA fragments. Samples on lane 2,4, and 6 are the same as 1,3, and 5 but were digested with a n l .
As expected, a 120-bp fragment is excised from the 5' end of the PCR amplified RARalmylcDNA.
primer set, we have been able to amplify these two specific breakpoint sites in all six acute phase APL patient samples tested.
Though chemotherapy is effective in producing complete remission and long-term cures, therapy with ATRA in APL results in complete remission, although the remissions do 585-3 4 0 9 , 140-, . not appear to be long term.I4 However, future studies using the combination of ATRA and chemotherapy could be a more successful approach to achieve long-term remission." Therefore, our data demonstrating a reliable approach for detection of minimal residual disease in APL and will be important for evaluating the effects of new therapeutic strategies. In addition, we have established a strategy to detect minimal residual leukemia in APL and have been able to identify the t(15;17) transcripts in five remission samples. Using our sensitive PCR assay it will now be possible to investigate whether the complete elimination of minimal residual leukemic cells will be necessary to achieve long-term remission in APL. Furthermore, quantitation of mRNA by PCR is now feasible.m22 Therefore, quantitation of fusion transcripts while the APL patient is in remission may provide additional information for predicting relapse. It will be important to determine whether there is heterogeneity in the detection of minimal residual disease in APL and how minimal residual disease correlates with therapeutic response and long-term remission.
